An Observational Study of Molecular profIling of Advanced and aggRessive ENdometrial Cancer and 1-st Line Treatment Approaches in Russian Federation

Plain-language summary

This observational study examines the molecular profile of tumors and first-line treatment approaches in patients with advanced and aggressive endometrial cancer in the Russian Federation. It is open to women aged 18 and older with newly diagnosed, advanced-stage (III-IV) endometrial cancer. It is a study without an assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

AstraZeneca

Start date

6/24/2025

Estimated completion

6/30/2027

Countries

Russia

Related genes

Locations

• Arkhangelsk, Russia
• Barnaul, Russia
• Chelyabinsk, Russia
• Irkutsk, Russia
• Izhevsk, Russia
• Krasnodar, Russia
• Krasnoyarsk, Russia
• Moscow, Russia
• Murmansk, Russia
• Obninsk, Russia
• Saint Petersburg, Russia
• Severodvinsk, Russia
• Sochi, Russia
• Tomsk, Russia
• Tver', Russia
• Ufa, Russia
• Vladivostok, Russia
• Yaroslavl, Russia
• Yekaterinburg, Russia

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Female patients aged ≥ 18 years old;
2. Signed ICF, including consent for archival FFPE tumor tissue block testing;
3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion;
4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others);
5. The presence of biopsy or postoperative archival FFPE tumor sample (block);
6. Availability of source medical documentation.

Exclusion Criteria:

1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.